PCVX · Vaxcyte, Inc.

Option shall vest over 36 months, 1/3 of which will vest on July 16, 2027 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.

Option is fully vested and exercisable.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026.

The price reported is a weighted-average price. The shares were sold at prices ranging from $56.595 to $57.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026.

The price reported is a weighted-average price. The shares were sold at prices ranging from $57.61 to $58.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.

The price reported is a weighted-average price. The shares were sold at prices ranging from $55.60 to $56.595. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.

The price reported is a weighted-average price. The shares were sold at prices ranging from $56.695 to $57.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Stock Option is fully vested and exercisable.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

The price reported is a weighted-average price. The shares were sold at prices ranging from $54.755 to $55.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

The price reported is a weighted-average price. The shares were sold at prices ranging from $53.755 to $54.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

The price reported is a weighted-average price. The shares were sold at prices ranging from $54.80 to $55.51. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Shares are held directly by a trust for the benefit of the Reporting Person's son.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

The price reported is a weighted-average price. The shares were sold at prices ranging from $53.77 to $54.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

The price reported is a weighted-average price. The shares were sold at prices ranging from $56.00 to $56.54. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

The price reported is a weighted-average price. The shares were sold at prices ranging from $55.815 to $56.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

The price reported is a weighted-average price. The shares were sold at prices ranging from $55.88 to $56.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Shares are held directly by a trust for the benefit of the Reporting Person's son.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

The price reported is a weighted-average price. The shares were sold at prices ranging from $53.77 to $54.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Shares are held directly by a trust for the benefit of the Reporting Person's son.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

The price reported is a weighted-average price. The shares were sold at prices ranging from $54.80 to $55.72. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

Option shall vest over 36 months, 1/3 of which will vest on June 17, 2027 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

Shares are held directly by a trust for the benefit of the Reporting Person's son.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026.

Option is fully vested and exercisable.

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

Option is fully vested and exercisable.

The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control.

Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control .

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.

The price reported is a weighted-average price. The shares were sold at prices ranging from $49.03 to $49.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.

The price reported is a weighted-average price. The shares were sold at prices ranging from $50.205 to $51.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.

The price reported is a weighted-average price. The shares were sold at prices ranging from $56.425 to $57.26. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.